--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-25-055915" form_type: "8-K" ticker: null cik: "0001741830" company_name: "Kronos Bio, Inc." filed_at: "2025-06-20T23:59:59+00:00" generated_at: "2026-05-19T01:36:32.256220+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # Kronos Bio acquired by Concentra Biosciences for $0.57/share plus CVR; delisting effective ## Summary - Tender offer closed June 18 with 44.5M shares (72.9% outstanding) tendered; merger completed June 20. - Shareholders receive $0.57 cash per share plus one non-transferable contingent value right (CVR) per share. - All conditions to tender offer and merger satisfied; shares to be delisted from Nasdaq and deregistered. - Board of directors resigned; new directors and officers from Concentra Merger Sub appointed (CEO Kevin Tang). - Company became wholly owned subsidiary of Concentra Biosciences; articles and bylaws amended. ## SEC filing metadata - accession: 0001213900-25-055915 - form_type: 8-K - cik: 0001741830 - company_name: Kronos Bio, Inc. - filed_at: 2025-06-20T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/ea0246047-8k_kronos.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-25-055915 - JSON: https://secwatch.observer/filing/0001213900-25-055915.json - Plain text: https://secwatch.observer/filing/0001213900-25-055915.txt ## Key facts - Executive change Kevin Tang was appointed as Chief Executive Officer at Kronos Bio, Inc.. - Action: appointed - Role: Chief Executive Officer source text: The executive officers of Merger Sub immediately prior to the Effective Time were: (i) Mr. Tang, Chief Executive Officer evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Roger Dansey resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Katherine Vega Stultz resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Taiyin Yang resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Joshua Kazam resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Norbert Bischofberger resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change David M. Tanen resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Elena Ridloff resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Deborah Knobelman resigned as other_named_officer at Kronos Bio, Inc.. - Action: resigned source text: Dr. Deborah Knobelman resigned from her position as an officer of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Roshawn Blunt resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Kevin Tang was appointed as Director at Kronos Bio, Inc.. - Action: appointed - Role: Director source text: The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang. evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - Executive change Arie Belldegrun resigned as Director at Kronos Bio, Inc.. - Action: resigned - Role: Director source text: at the Effective Time, each of Arie Belldegrun, M.D., Norbert Bischofberger, Ph.D., Roshawn Blunt, Roger Dansey, M.D., Joshua Kazam, Elena Ridloff, CFA, Katherine Vega Stultz, David M. Tanen and Taiyin Yang, Ph.D. resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm - M&A Transactions Kronos Bio, Inc. underwent a change of control involving Concentra Biosciences, LLC for $0.57 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2025-06-20). - Action: change of control - Counterparty: Concentra Biosciences, LLC - Consideration: $0.57 in cash per Share plus one non-transferable contractual contingent value right per Share - Closing: 2025-06-20 source text: 2025, Merger Sub completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “ Shares ”), in exchange for (i) $0.57 in cash per Share (the “Cash Amount”); plus (ii) one non-transferable contractual contingent value right per Share (each, a “CVR,” and each CVR together with the Cash Amount, the evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.